FLT3 inhibitors in the treatment of AML
Breakthroughs in the treatment of elderly patients with AML
Future therapies for AML: bispecifics and small molecule inhibitors
MRD Focus: why measurable residual disease testing is the future
Bruno Paiva et al.
IDH inhibitors for AML and MDS